Neil M. Iyengar, MD

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss how to decide on treatment for patients with advanced or metastatic HER2-positive breast cancer who have central nervous system metastases.

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.

Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.

Dr. Neil M. Iyengar closes the discussion with preliminary results from a phase I study, thoughts on use of biosimilars, and other in-progress trials of interest.

Clinically relevant advice for the monitoring and management of pulmonary complications in patients with HER2+ mBC.

Discussion centered around the latest data and guideline updates, and how these changes affect therapy sequencing in the first, second, and third lines of treatment.

Insights concerning the selection of effective treatment approaches for patients with HER2+ mBC presenting with brain metastases and other complications.

An expert breast medical oncologist discusses recent changes to HER2+ mBC treatment guidelines due to key findings from the DESTINY-Breast03 trial.

Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.

A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.

Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.

Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.

Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.

Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.

Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.

Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.

Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.

Shared insight on the optimal sequencing of therapeutic agents for patients undergoing treatment for HER2+ metastatic breast cancer.

Comprehensive insight on therapeutic classes and agents approved in the setting of HER2+ metastatic breast cancer, with a specific focus on how these therapies fit into current treatment strategies.

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

Strategies to help breast oncologists counsel patients on metabolic conditions when treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitors.

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.